Kobayashi Pharmaceutical Co (KBYPF) Stock Statistics & Valuation Metrics

Kobayashi Pharmaceutical Co has a market cap or net worth of $2.66B. The enterprise value is $363.51B.

Kobayashi Pharmaceutical Co has 78,050,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kobayashi Pharmaceutical Co’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 6.77%.

The current PE Ratio of Kobayashi Pharmaceutical Co is ―. Kobayashi Pharmaceutical Co’s PEG ratio is -1.73.

In the last 12 months, Kobayashi Pharmaceutical Co had revenue of 165.74B and earned 3.66B in profits. Earnings per share was 49.18.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Kobayashi Pharmaceutical Co pays an annual dividend of $0.396, resulting in a dividend yield of 2.01%

Kobayashi Pharmaceutical Co upcoming earnings date is May 8, 2026, TBA (Confirmed).

Kobayashi Pharmaceutical Co as a current ratio of 2.47, with Debt / Equity ratio of 0.32%

In the past 12 months, Kobayashi Pharmaceutical Co has paid 83.00M in taxes.

Kobayashi Pharmaceutical Co EV to EBITDA ratio is 27.31, with an EV/FCF ratio of 27.71.

Kobayashi Pharmaceutical Co has $69.67B in cash and marketable securities with $749.00M in debt, giving a net cash position of $68.92B billion.

Gross margin is 51.11%, with operating margin of 9.00%, and net profit margin of 2.21%.

The average price target for Kobayashi Pharmaceutical Co is $33.06, which is 11.43% higher than the current price. The consensus rating is Moderate Sell